Navigation Links
New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians

HAYWARD, Calif., Oct. 11 /PRNewswire/ -- Guava Technologies today launched a new corporate website with an infrastructure focused around its main audiences: Life Scientists, Flow Cytometrists, and Clinicians.

With flow cytometry being an essential tool for cell analysis, Guava Technologies is dedicated to finding innovative ways to make the technology as practical as possible for all life scientists and clinicians who work with cells. This dedication is obvious from the audience-centric organization of the new site, where the main choices on the home page for further investigation are targeted to the unique needs of the company's main markets: Life Science Research (i.e., pharma/biotech, academia/government, clinical research), Flow Cytometry, and Clinical Diagnostics.

While the website does offer traditional navigation, those links are secondary. The site is obviously built around the company's desire to serve its key market segments and stakeholders. According to Lawrence Bruder, CEO, the audience-centric organization was the obvious choice from the beginning: "Those individuals are the reason we are in business; the reason our employees come to work every day," said Mr. Bruder, "so given the importance of our website as a vehicle for two-way communication with them, it just made sense to focus it on their needs."

Guava Technologies encourages everyone interested in flow cytometry or the company to visit the site at, and to let the company know what it can do to further improve the site based on their needs and interests.

Guava Technologies is a private biotechnology and medical device company. In 2001, it introduced the first commercial benchtop microcapillary flow cytometer with easy-to-use, assay-specific reagents and software. Since then, it has introduced numerous new systems and assays, always focusing on making flow cytometry more practical for life scientists and clinicians. Guava Systems do not require sheath fluid so accommodate smaller sample volumes, generate less waste, have lower daily operate costs, and are easier to set-up and maintain than traditional flow cytometers. And, all Guava Systems perform direct, absolute cell counts without reference beads. True to the company's goal, virtually any scientist or clinician can learn to operate a Guava System in less than one day.

SOURCE Guava Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Selecting siRNA Sequences to Incorporate into the pSilencer Vectors
2. Pre-eminent, web-based companies owe success to corporate venturing
3. Corporate Social Responsibility - Burden, sham, or golden opportunity?
4. Corporate venturing can nurture software success
5. Enrons dilemma: A corporate governance nightmare
6. Getting beyond the vortex of corporate mediocrity
7. Corporate control begins with a strong board
8. Directors more assertive in corporate governance
9. The black hole of corporate branding
10. Corporate Americas hidden deficit
11. Business professor launches corporate reporting study
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):